TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10372608
Drug: Novel antipsychotics
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel antipsychotics (olanzapine, quetiapine, risperidone, sertindole, zotepine)
Study: 1692948
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sublingual nifedipine
Study: 28129312
Drug: Glycopyrrolate 1
Normalized name: glycopyrrolate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 1 mg
Study: 28129312
Drug: Glycopyrrolate 2
Normalized name: glycopyrrolate 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 2 mg
Study: 23845629
Drug: Reduced soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced soybean lipid emulsion (1.0 g/kg/day)
Study: 23845629
Drug: Standard soybean
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard soybean lipid emulsion (3 g/kg/day)
Study: 21107317
Drug: Clinical Antipsychotic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
Study: 19120324
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) - StarLux, Lux G prototype handpiece, 500-670 and 870-1400 nm, 5-10 ms
Study: 17760715
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication (omeprazole, amoxicillin, and clarithromycin)
Study: 9569998
Drug: ABT-761 (10-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-761 (10-160 mg)
Study: 2839724
Drug: Susta II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Susta II (12.4-g soy polysaccharide/2000 kcal)
Study: 2839724
Drug: Enrich (38.5-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrich (38.5-g soy polysaccharide/2000 kcal)
Study: 1219276
Drug: Idulian (syrup)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idulian (syrup) 2 x 0.5 mg
Study: 28710329
Drug: Ranolazine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (500 mg twice daily, increased to 1,000 mg twice daily after week 2)
Study: 24156737
Drug: Poor-effort (treatment)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor-effort (treatment) condition
Study: 18281410
Drug: Fluoxetine (stricter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (stricter definition)
Study: 16688999
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine for Yiqi Yangyin Quyu (YYQ) and prednisone
Study: 11600560
Drug: Triglyceride infusion
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride infusion
Study: 10615946
Drug: Triglyceride infusion
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride infusion with hyperinsulinemic clamp
Study: 29182037
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.5 mg/kg/day
Study: 22869571
Drug: TD-1792 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TD-1792 (2 mg/kg i.v. q24h)
Study: 22869571
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g i.v. q12h)
Study: 19927154
Drug: Aliskiren 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 75 mg once daily, increased to 150 mg and then to 300 mg if needed
Study: 17621602
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mg kg(‐1) h(‐1)
Study: 10850585
Drug: Preemptive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive therapy with intravenous ganciclovir and CMV‐hyperimmunoglobulin
Study: 10850585
Drug: Therapy only
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy only at onset of clinical symptoms (Control)
Study: 8712444
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 12.5 mg
Study: 8712444
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 50 mg
Study: 8712444
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 75 mg
Study: 8712444
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine 100 mg
Study: 6178096
Drug: Ceruletide (CRL)
Normalized name: ceruletide diethylamine
DrugBank: Ceruletide (DB00403)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceruletide (CRL) at a dose of 2 ng/kg/min
Study: 26777137
Drug: Simeprevir 100
Normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simeprevir 100 mg QD plus PR
Study: 26777137
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg QD plus PR
Study: 23983966
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day quercetin
Study: 23983966
Drug: 1000 mg/day
Normalized name: RibaTab 1000 MG/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg/day quercetin
Study: 19497244
Drug: Olanzapine 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10, 20, and 40 mg/day (combined)
Study: 17256809
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injections (30 units Botox or 90 units Dysport)
Study: 17256809
Drug: 0.2% Nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Nitroglycerin ointment applied three times daily for 8 weeks
Study: 17256809
Drug: 0.2% Nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Nitroglycerin ointment
Study: 8681500
Drug: Doxazosin (1-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-8 mg daily)
Study: 8681500
Drug: Enalapril (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5-20 mg daily)
Study: 1977577
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral interferon alpha
Study: 341964
Drug: Pharmacological doses
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological doses of oxytocin (2.6 mU/minute increasing to 422.4 mU/minute)
Study: 341964
Drug: Physiological doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological doses of oxytocin (2.6 to 13.2 mU/minute)
Study: 22191292
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and IV contrast-enhanced MDCT (Gp1)
Study: 19436042
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 60-min consultation, four weekly appointments with HSCS, and leaflets
Study: 19436042
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 60-min consultation, four weekly appointments with HSCS, and scheduled appointment at community-based service
Study: 15313991
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac solution (1.5% wt/wt diclofenac sodium in a carrier containing dimethyl sulfoxide [DMSO])
Study: 8288743
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral melatonin
Study: 8288743
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg testosterone propionate i.m. (TP)
Study: 3086959
Drug: Flunarizine 5
Normalized name: flunarizine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 5 mg a day for patients over 10 kg, 5 mg every two days for patients under 10 kg (3 months)
Study: 29091464
Drug: T-LPP supplement
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-LPP supplement
Study: 24269926
Drug: Methotrexate (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (initial weekly dose of 10 mg, escalating to 25 mg/week) + infliximab (5 mg/kg body weight at weeks 1, 3, 7, and 14, and every 8 weeks thereafter)
Study: 24269926
Drug: Infliximab alone
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab alone (5 mg/kg body weight at weeks 1, 3, 7, and 14, and every 8 weeks thereafter)
Study: 23528365
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel with 1% standardized extract of Sphaeralcea angustifolia
Study: 23528365
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel with 2% diclofenac
Study: 18208957
Drug: Telehomecare units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehomecare units with peripheral devices (blood-pressure monitor, weight scale, glucometer, pulse oximeter) installed in patients' homes, used daily for data collection.
Study: 25484177
Drug: Crocin (30mg/day;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crocin (30mg/day; 15mg BID) plus SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day)
Study: 25484177
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two placebo tablets per day) plus SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day)
Study: 23532801
Drug: 5-grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-grass pollen tablets
Study: 21252745
Drug: Letrozole 10
Normalized name: letrozole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 10 mg daily for 3 days followed by 800 micrograms of vaginal misoprostol
Study: 19276230
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion to obtain appropriate FFA concentrations
Study: 19925723
Drug: Loose larval
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose larval therapy
Study: 19925723
Drug: Bagged larval
Normalized name: Bombyx mori larva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bagged larval therapy
Study: 29188875
Drug: Protein-enriched milk
Normalized name: milk protein concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein-enriched milk (2 x 0.4 L/d)
Study: 29188875
Drug: Isocaloric carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric carbohydrate drink (2 x 0.4 L/d)
Study: 24978834
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg)
Study: 21752522
Drug: Cryptic shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryptic shock group (lactate ≥ 4mmol/L and normotension)
Study: 15116058
Drug: Gemfibrozil, 600
Normalized name: Gemfibrozil, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil, 600 mg, twice daily for 7 days
Study: 3555944
Drug: Phenobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (100 mg/day for 2 months)
Study: 29509266
Drug: Control (hip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hip arthroplasty and symptomatic/supportive treatment)
Study: 27605607
Drug: Cabergoline (D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (D2 agonist)
Study: 16603132
Drug: Pergolide (D1/D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (D1/D2 agonist)
Study: 24464452
Drug: Mild/minimal stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild/minimal stimulation protocol of recombinant FSH (rFSH) combined with GnRH antagonist (Group A)
Study: 24464452
Drug: Standard long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard long protocol of rFSH combined with GnRH agonist (Group B)
Study: 12699607
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) via videoconferencing (VC)
Study: 12699607
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) face-to-face (F2F)
Study: 10720118
Drug: Short-chain fatty
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-chain fatty acids (SCFA) enema administered twice daily for 3 weeks
Study: 10720118
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution administered twice daily for 3 weeks
Study: 8737132
Drug: Sparfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 6 additional days)
Study: 8737132
Drug: Sparfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (200 mg on day 1 followed by 100 mg daily for 2 additional days)
Study: 8737132
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg once daily for 7 days)
Study: 1343113
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dexfenfluramine (dF) twice daily for 3 days prior to glucose infusion; 30 mg dF 90 min before the test.
Study: 1343113
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dexfenfluramine (dF) before the test.
Study: 1343113
Drug: dF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dF treatment in obese subjects for one month.
Study: 1343113
Drug: dF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dF treatment in obese subjects with relative fasting hyperinsulinemia (> 100 pmol/l).
Study: 1343113
Drug: dF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dF treatment in obese subjects with low fasting plasma insulin (< 100 pmol/l).
Study: 26700705
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b (IFN) 3 × 10(6) IU subcutaneously 3 times a week for 4 weeks and 13-cis-retinoic acid (RA) 40 mg orally daily for 30 days during radiation therapy
Study: 26700705
Drug: Cisplatin 40
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40 mg/m(2) weekly for 5 weeks during radiation therapy
Study: 18022679
Drug: Acute nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute nicotine (7 mg patch for 45 min)
Study: 15901750
Drug: 60% ethanolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60% ethanolic extract from the roots of Echinacea angustifolia, 2.5-mL dose
Study: 12934777
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin 10 mg/d
Study: 12934777
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine 4 mg/d
Study: 10822316
Drug: losartan 50-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: losartan 50-100 mg/day (n = 15)
Study: 10822316
Drug: enalapril 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 2.5-10 mg/day (n = 14)
Study: 8867163
Drug: Midazolam 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 3.75 mg
Study: 1518695
Drug: Surfactant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant therapy during clinical trial participation
Study: 6712393
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tobramycin plus cefamandole
Study: 6712393
Drug: Interrupted infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interrupted infusion of tobramycin plus cefamandole
Study: 6860416
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of tobramycin
Study: 6712393
Drug: Interrupted infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interrupted infusion of tobramycin
Study: 28079236
Drug: CHO-GLN beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-GLN beverage (12.5% maltodextrin plus 15 g GLN)
Study: 26841875
Drug: interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: interpersonal psychotherapy (IPT) + treatment as usual (TAU)
Study: 22538183
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis brief intervention
Study: 17563866
Drug: Low-dose, weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, weekly docetaxel chemotherapy
Study: 11263614
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (Amiodarone)
Study: 9623426
Drug: Local anaesthetics
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anaesthetics (1 ml kg‐1 of a mixture of 0.25% bupivacaine with epinephrine and 1% lidocaine in equal parts)
Study: 3830246
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 to 0.88 mg daily
Study: 29289332
Drug: 100μg levothyroxine
Normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100μg levothyroxine sodium tablet once daily for 6 months
Study: 29289332
Drug: Tablet dissolution
Normalized name: Witch Hazel 30 mg in 30 mL TOPICAL PATCH [LEADERS INSOLUTION COCONUT LIFTING RECOVERY MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet dissolution rate (BP/EP 2014 & USP 2014)
Study: 23224567
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment followed by balloon treatment (group 1)
Study: 23224567
Drug: Balloon treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon treatment (group 2)
Study: 12928051
Drug: ‐174 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‐174 CC genotype
Study: 12928051
Drug: ‐174 CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‐174 CC and VNTR DD genotypes
Study: 6605565
Drug: Rifampin 20
Normalized name: rifampin 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 20 mg/kg once daily for four days
Study: 19743543
Drug: Ranolazine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine (500 mg to 1000 mg twice a day) added to ongoing amlodipine therapy
Study: 15333452
Drug: Oral lactobacillus
Normalized name: Lactobacillus acidophilus Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lactobacillus
Study: 8880290
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine clonixinate 4 mg x kg‐1
Study: 8880290
Drug: Intravenous lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lysine clonixinate 6 mg x kg‐1
Study: 30202916
Drug: Daily tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily tobacco consumption (10 g/day increase)
Study: 28477944
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (1.7 g/kg per day) during hospitalization, daily protein supplement (18.8 g), and 3 weekly resistance training sessions for 12 weeks after discharge
Study: 25391814
Drug: Psyllium (7.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (7.0 g daily)
Study: 16636130
Drug: r‐metHuLeptin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuLeptin therapy
Study: 12801313
Drug: montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast 10 mg/desloratadine 5 mg combination
Study: 12801313
Drug: montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast 10 mg alone
Study: 8852914
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir therapy (300 mg/m2/dose, administered either twice daily or three times per day for 6 months)
Study: 8852914
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir therapy
Study: 1497125
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 micrograms/kg bolus, 2 micrograms kg‐1 h‐1 infusion)
Study: 1497125
Drug: Pentazocine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Study: 1497125
Drug: Ketamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (2 mg/kg bolus, 0.8 mg kg‐1 h‐1 infusion)
Study: 6140128
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tiapride 3-times daily for 14 days
Study: 6140128
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg glafenine 3-times daily for 14 days
Study: 22433921
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 20 mg b.i.d.
Study: 22433921
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 10 mg b.i.d.
Study: 22433921
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 20 mg q.d. (control)
Study: 19505390
Drug: Nebulized flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized flunisolide (40 microg/kg twice daily for 7 days, then 20 microg/kg twice daily for 14 days)
Study: 19505390
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (0.5 mg twice daily for 7 days, then 0.25 mg twice daily for 15 days)
Study: 11682426
Drug: Gel-pad
Normalized name: SCARCARE Gel-Pad Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-pad
Study: 11682426
Drug: 1000-mL lactated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000-mL lactated Ringer's bag
Study: 12748510
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid supplementation (approximately 200 mg/d)
Study: 10807815
Drug: MDI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI with Nebuchamber (placebo MDI through NESD, four puffs) and salbutamol 0.5 mL (2.5 mg) as NWA (group I, n = 19)